LabReflex
Making diagnostics clearer, smarter, and more effective. Bringing the story behind the numbers.
Latest Episodes
The Four Forces Shaping the Lab this week
December 8, 2025
LabReflex Show Notes Episode Title: Diagnostics at a Crossroads: Four Forces Reshaping the Future of Labs Hosts: Chris Zahner and Aakash Episode Type: Industry analysis and strategic discussion Summary In this episode, we break down four major forces reshaping the clinical laboratory landscape right now: Automation and the redistribution of diagnostic work. Genomics as a business driver rather than a niche specialty. Regulators pushing healthcare toward biomarker-defined disease. Instability across the healthcare system — including payer disputes, hospital closures, and laboratory consolidation. We connect these trends to real decisions labs are facing today: how to staff, what technologies to invest in, how to think about outreach, what “contribution” actually means inside a hospital, and how to prepare for structural changes in the diagnostic market. 1. Automation Is Redrawing Where Diagnostic Work Happens Inside the Lab Automation is moving far beyond sample-to-answer instruments. We now have: Beckman Coulter + IDT developing end-to-end NGS library prep and hybrid-capture workflows. Source: Beckman/IDT partnership announcement https://www.beckman.com/news Mission Bio’s Tapestri platform allowing DNA and RNA measurements from the same single cell. https://missionbio.com/tapestri/ These tools shift technologist time away from pipetting and toward QC, troubleshooting, and informatics. Some labs report more than 60% of FTE time now tied to exception handling rather than manual processing. Outside the Lab Roche’s CLIA-waived Bordetella PCR (~15 min TAT) illustrates the continuing drift of molecular diagnostics toward the clinic. Source: Roche Diagnostics https://diagnostics.roche.com/ The story is not “labs are going away.” The story is: labs are becoming the stewards of increasingly distributed diagnostic ecosystems. 2. Genomics and Predictive Diagnostics as a Business Strategy BillionToOne BillionToOne’s IPO put the company at roughly a $4.4B valuation, with 82% year-over-year revenue growth. This is one of the clearest signals that genomics is becoming a major financial pillar of diagnostics rather than a boutique offering. Source: Reuters coverage of BillionToOne IPO https://www.reuters.com/ Nightingale Health Nightingale’s NMR-based platform can generate multiple risk scores from a single blood sample. Finland’s largest private provider (Terveystalo) rolled it out across its full client base. https://nightingalehealth.com/ https://www.terveystalo.com/ This marks a shift from “diagnose disease” to “predict disease,” which has enormous implications for test menus and reimbursement patterns. CRISPR Lyme Test Developed by High School Students A high school iGEM team created a CRISPR-based Lyme assay that can detect infection in about 48 hours (compared to the 7–14 day window for serology). https://igem.org/ This is a reminder of how quickly new diagnostic modalities can appear, and how democratized the innovation pipeline has become. 3. Regulation: Biomarkers and CRISPR Are Rewriting the Diagnostic Rulebook EMA Parkinson’s Concept Paper The EMA issued a long-awaited revision of its Parkinson’s disease guidance. The document pushes strongly for: Biomarkers in patient selection Biomarkers in disease staging and progression Biomarkers in treatment-response measurement Integration of digital measures and device-based endpoints This is the same transformation oncology went through years ago—moving from clinically defined disease to biologically defined disease. EMA Parkinson’s Concept Paper: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-parkinsons-disease_en.pdf CRISPR Diagnostics CRISPR-based assays are sensitive to contamination, behave differently from PCR, and do not fit cleanly into current CLIA validation frameworks. Labs will need new QC materials and updated validation approaches for these assays to become routine. The main regulatory message: diagnostics are moving from a supporting tool to a defining element of disease classification and therapy development. 4. System Instability: Payer Turmoil, Bifurcation, and Consolidation Labcorp Acquires CHS Outreach Operations Labcorp purchased the outreach and ambulatory lab operations of Community Health Systems (CHS) across 13 states in a deal worth about $194 million. Press coverage: https://www.businesswire.com/ This is part of a larger pattern: financially strained health systems offloading lab assets, while national labs consolidate. Payer Disputes Two recent examples illustrate how quickly lab volume can be disrupted: UNC Health went out of network with Cigna on Dec 1, 2025, affecting tens of thousands of patients. https://www.wral.com/ Aspirus Health (St. Luke’s) and Blue Cross Blue Shield Minnesota are in a dispute affecting up to 2 million insured individuals. https://www.mprnews.org/ For labs, these disputes result in abrupt shifts in outpatient volume, increases in patient self-pay, and very unstable revenue cycles. Hospital Bifurcation Some systems are closing service lines or entire hospitals; others are reporting their strongest financial performance ever. Examples: Vibra Specialty Hospital in Portland closing with roughly 300 layoffs. https://www.koin.com/ More than 140 rural hospitals have closed since 2010, with over 600 at current risk. Chartis Rural Safety Net Report: https://www.chartis.com/ Meanwhile, HCA continues to post record financial performance. https://investor.hcahealthcare.com/ This bifurcation translates directly into lab investment patterns: some labs modernize rapidly, others freeze capital spending, delay hires, or outsource. Interpreting “Contribution” Correctly A recurring misconception: reported “33% contribution margin” for outreach programs is not incremental contribution in the managerial accounting sense. It is typically service-line contribution after allocation of shared and indirect costs across the health system, not the actual incremental economics of adding a new outreach client. This distinction matters because misinterpreting contribution margin leads to poor decisions about outsourcing or downsizing lab services. Sources that discuss lab outreach margin structures: Chi Solutions / CLP summarizing outreach financials (historical) https://www.captodayonline.com/ Analysis via TechTarget https://www.techtarget.com/ Industry-level gross margin context: CSI Market laboratory industry gross margin (~43%)
Listen Now →
Workforce and AI Governance
November 24, 2025
Show notes 1. Workforce First We begin by tackling the workforce crisis in the clinical lab world: new data show 1 in 4 healthcare workers are considering leaving the industry — and our labs are not immune. What does that mean for QC, turnaround times, validation, and staffing resilience? We walk through actionable steps labs can take today — from cross-training to automation prioritization and career ladder improvements. 2. AI Governance Gaps Next: why AI is being adopted everywhere but few labs are ready. We reference CAP’s AI Committee and its charge to “create and maintain an AI strategy” for laboratories and pathology practice. We present our LabReflex 5-Step AI Governance Framework, aligned with CAP principles, to help labs build their own strategy. That includes inventory, risk-tiering, validation, monitoring, and policy. We highlight how labs can lead rather than react. 3. AI Diagnostic Wins Moving from risk to opportunity: we showcase emerging successes in lab AI. For example, machine-learning models predicting urine culture outcomes and digital pathology classifiers like bone marrow smear AI. These are tangible signs the lab of the future is here — and we map out how labs can pilot or prepare for these technologies, not just watch them. 4. Infectious Disease Alerts Finally, we cover the pressing lab-relevant outbreaks and infectious signals: the first U.S. human case of a novel bird flu strain (H5N5), a significant measles resurgence (highest U.S. annual case-count in decades), and a backdrop of a severe influenza season. For each, we break down what labs should be doing: specimen routing, surge workflows, assay verification, TAT planning, and public‐health coordination. Wrapping Up We conclude by tying all four themes together — workforce + governance + innovation + outbreak readiness — showing how they converge on the lab’s mission: remain resilient, lead innovation, and ensure patient safety in turbulent times. Key Resource Links CAP Artificial Intelligence (AI) Committee – charge & strategy: CAP AI Committee - College of American Pathologists CAP AI in Pathology Resources – deep dive, webinars, review series: CAP AI in Pathology - College of American Pathologists
Listen Now →
Government Returns!
November 17, 2025
Government Returns! Episode Summary: In this episode of LabReflex, Dr. Chris Zahner breaks down four major developments every laboratory should be watching closely. The federal government is open again after the longest shutdown in U.S. history — but agencies are not fully back to normal. At the same time, severe global flu activity is signaling a challenging U.S. season, host-response diagnostics are advancing rapidly (including UTMB’s own TriVerity validation study), and the FDA’s new fast-track pathway for personalized therapies is poised to shift significant workload onto clinical labs. This solo episode gives you a clear, practical, lab-centered view of what’s happening now and what’s coming next. 🔹 Topics Covered 1. Government Shutdown Ends — But Labs Should Stay Alert Federal agencies like FDA, CMS, and NIH have reopened. Operations are funded only through a temporary patch. Regulatory guidance, reimbursement updates, and grants all have backlogs. Labs should expect delays and uncertainty into early 2026. 2. Global Flu Season Looks Severe — What U.S. Labs Should Prepare For Several countries are experiencing unusually heavy flu activity. The U.S. typically follows global trends by 4–8 weeks. Expected lab impacts: Increased PCR testing for flu, RSV, and COVID More full respiratory panels More bacterial coinfection testing (PCT, CRP, cultures) Potential assay verification for strain drift Winter readiness recommendations for labs: Staffing plans Inventory and supply chain checks Clear respiratory testing algorithms Early communication with ED and clinicians 3. Host-Response Diagnostics — A New Diagnostic Era Host-response diagnostics read immune activity instead of pathogen presence. UTMB is actively validating TriVerity, an mRNA-based immune-response test. Other major technologies: MeMed, Cytovale, Immunexpress, Predigen. Why labs should care: Faster viral vs. bacterial differentiation Early sepsis severity scoring Better ED triage during respiratory season Changing test menus and workflows in clinical labs 4. FDA’s Personalized Therapy Pathway — And the New Burden on Labs FDA is fast-tracking personalized therapies using mechanistic evidence. Smaller clinical trials shift post-market evidence collection to labs. Labs should prepare for: New companion diagnostics Rare or patient-specific LDT development Complex molecular biomarkers Long-term toxicity/genomic monitoring Molecular, genetics, and pathology labs will feel the pressure first. 🔹 Key Takeaways Government is open, but regulatory and reimbursement pipelines are still slow. A heavy flu season is likely coming — labs must prepare early. Host-response diagnostics are quickly moving from research to clinical practice. Personalized therapies require personalized diagnostics — and labs will be the backbone.
Listen Now →About LabReflex
Diagnostics sit underneath almost every decision in medicine, but most people only see the numbers and not the story behind them. LabReflex brings that story forward, giving it context, and helping people understand what matters and what does not.
Direct, practical, and grounded in actual work rather than theory. Join Dr. Christopher Zahner, a clinical pathologist and former NASA engineer, as he explores the intersection of precision, systems thinking, and diagnostic medicine.
Meet the Creator